Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Sells 30,156 Shares

Posted by Stanley Muller on Apr 15th, 2025

Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. sold 30,156 shares of the business’s stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $11.14, for a total value of $335,937.84. Following the transaction, the insider now directly owns 3,094,316 shares in the company, valued at $34,470,680.24. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Friday, April 4th, Saba Capital Management, L.P. sold 6,889 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.57, for a total transaction of $79,705.73.
On Wednesday, April 2nd, Saba Capital Management, L.P. sold 29,102 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.28, for a total value of $357,372.56.
On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.58, for a total value of $611,677.34.
On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.01, for a total transaction of $428,315.22.
On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.62, for a total transaction of $2,724.00.
On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.75, for a total transaction of $502,370.00.
On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.95, for a total transaction of $599,668.65.
On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.03, for a total value of $25,899.38.
On Friday, January 31st, Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.27, for a total value of $216,090.61.
On Wednesday, January 29th, Saba Capital Management, L.P. sold 11,674 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.12, for a total value of $164,836.88.

Abrdn Life Sciences Investors Stock Performance

Shares of HQL opened at $11.78 on Tuesday. The business’s fifty day moving average price is $12.95 and its 200 day moving average price is $13.78. Abrdn Life Sciences Investors has a 12-month low of $10.55 and a 12-month high of $15.90.

Abrdn Life Sciences Investors Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, February 21st were given a $0.47 dividend. The ex-dividend date of this dividend was Friday, February 21st. This represents a $1.88 dividend on an annualized basis and a dividend yield of 15.96%.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

A number of large investors have recently bought and sold shares of the business. 180 Wealth Advisors LLC raised its position in shares of Abrdn Life Sciences Investors by 0.9% during the 1st quarter. 180 Wealth Advisors LLC now owns 136,122 shares of the company’s stock worth $1,727,000 after purchasing an additional 1,247 shares during the period. Ameriprise Financial Inc. increased its position in Abrdn Life Sciences Investors by 7.5% in the fourth quarter. Ameriprise Financial Inc. now owns 153,396 shares of the company’s stock worth $1,999,000 after buying an additional 10,742 shares during the period. Jane Street Group LLC bought a new stake in Abrdn Life Sciences Investors in the fourth quarter valued at $290,000. Stifel Financial Corp boosted its holdings in shares of Abrdn Life Sciences Investors by 67.1% during the fourth quarter. Stifel Financial Corp now owns 28,341 shares of the company’s stock valued at $372,000 after acquiring an additional 11,378 shares during the period. Finally, Guggenheim Capital LLC bought a new position in shares of Abrdn Life Sciences Investors during the fourth quarter worth about $211,000. Institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.